ArticleOphthalmology2025
Incidence of Endophthalmitis after Cataract Surgery in the Setting of Uveitis and Immunosuppressive Therapy within the IRIS® Registry.
Article in Ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo determine the differences in incidence of acute postoperative endophthalmitis after cataract surgery in the setting of uveitis and immunosuppressive therapy using the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight).
designRetrospective cohort study.
participantsPatients undergoing cataract surgery in the United States from 2013 to 2023.
methodsThe IRIS Registry was queried to identify cataract surgeries performed between January 1, 2013, and March 21, 2023. Postoperative endophthalmitis was identified based on endophthalmitis diagnosis codes and vitreous tap and intravitreal antibiotic injection within 60 days after surgery. Cases with a recent noninfectious uveitis diagnosis within 1 year before cataract surgery were also identified. Active use of systemic corticosteroids and immunosuppressives was determined using drug names and the National Library of Medicine Rx Concept Unique identifier. Eyes that underwent cataract surgery were classified into 4 groups: Group A: Eyes with no uveitis in patients with no concurrent systemic corticosteroid or immunosuppressive treatment (general population). Group B: Eyes with recent uveitis in patients with no concurrent systemic corticosteroid or immunosuppressive treatment. Group C: Eyes with no uveitis in patients with concurrent systemic corticosteroid or immunosuppressive treatment. Group D: Eyes with recent uveitis in patients with concurrent systemic corticosteroid or immunosuppressive treatment. Multivariable logistic regression was performed to evaluate the likelihood of endophthalmitis.
main outcome measuresIncidence of acute-onset postoperative endophthalmitis in eyes with a uveitis diagnosis and in eyes of patients under systemic corticosteroid and immunosuppressive therapy.
resultsA total of 9 742 773 cataract surgeries were identified; of those, 128 254 were in patients on systemic corticosteroids or immunosuppressives at the time of surgery. The incidence of acute postoperative endophthalmitis within 60 days after surgery was 0.058%, 0.468%, 0.137%, and 0.964%, in groups A, B, C, and D, respectively. The highest incidence of endophthalmitis diagnoses was in eyes with uveitis diagnoses; however, among eyes with and without uveitis, endophthalmitis incidence was higher in patients treated with immunosuppressives or corticosteroids. Multivariate logistic regression analysis revealed that systemic corticosteroids were more associated with endophthalmitis compared with systemic immunosuppressives.
conclusionsUnderlying uveitis diagnosis, systemic corticosteroids, and immunosuppressives are associated with an increased likelihood of acute postoperative endophthalmitis after cataract surgery. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.